Generics And Price Cuts Hit Novartis’s Japan, Emerging Market Sales
This article was originally published in PharmAsia News
Novartis, whose first quarter pharmaceuticals performance was weighed by Gleevec patent expiries, also suffered from weak sales in Japan and some emerging markets mainly due to impact from generics and price reductions.
You may also be interested in...
Faced with the risk of losing their investment from a possible stock delisting amid prosecutors’ probes into company’s management, SillaJen’s individual minority shareholders are demanding the Korea Exchange resume trading of the biotech’s stock, in a rare united move.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll on the Korean firm and partner Evolus as they face a 10-year ban on imports of their product to the US.